Non Hodgkin Lymphoma Clinical Trial

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Summary

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of CD19-positive relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).

Must have met the following criteria for prior treatment:

Participants with aggressive NHL must have received at least 2 lines of systemic therapy (if not intended for transplant, have already undergone or be unwilling or unable to undergo chimeric antigen receptor [CAR] T-cell therapy to be eligible), or at least 3 lines of systemic therapy. Previous therapy must have included a CD20-targeted agent and an anthracycline or alkylator.
Participants with follicular lymphoma (FL) must have received at least 2 lines of systemic therapy and have high-risk disease. Previous therapy must have included a CD20-targeted agent and an alkylator.
Participants with marginal zone lymphoma (MZL) must have received at least 2 prior systemic therapies.
Measurable disease on screening evaluations.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function.
Life expectancy of ≥12 weeks.

Exclusion Criteria:

Any condition that confounds the ability to interpret data from the study.
Central nervous system (CNS)-only involvement by malignancy. (Note: participants with secondary CNS involvement are allowed.)
Prior allogeneic stem cell transplant.
Presence of clinically significant CNS pathology.
Other comorbid conditions defined in the protocol.
Use of prohibited medications within the washout period defined in the protocol.

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

75

Study ID:

NCT05336409

Recruitment Status:

Recruiting

Sponsor:

Century Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 12 Locations for this study

See Locations Near You

University of Southern California - Norris Comprehensive Cancer Center
Los Angeles California, 90033, United States More Info
Dr Yaghmour
Contact
323-865-3170
University of California San Diego, Moores Cancer Center
San Diego California, 92093, United States More Info
Benjamin Heyman
Contact
858-822-6100
[email protected]
Medstar Georgetown University Hospital
Washington District of Columbia, 20007, United States More Info
Dr. Renteria
Contact
202-444-0939
[email protected]
University of Kentucky - Markey Cancer Center
Lexington Kentucky, 40536, United States More Info
Dr. Chaitanya Iragavarapu
Contact
859-257-4488
[email protected]
Henry Ford Hospital
Detroit Michigan, 48202, United States More Info
Dr Mattour
Contact
313-916-1266
Levine Cancer Institute
Charlotte North Carolina, 28204, United States More Info
Dr Moyo
Contact
980-442-2301
University of Cincinnati Medical Center
Cincinnati Ohio, 45229, United States More Info
Dr Latif
Contact
513-584-7824
Oncology Hematology Care, Inc-Kenwood
Cincinnati Ohio, 45236, United States More Info
Dr. James Essell
Contact
513-751-2273
[email protected]
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States More Info
Dr. Olalekan Oluwole
Contact
615-875-0060
[email protected]
Houston Methodist Research Institute
Houston Texas, 77030, United States More Info
Dr. Pingali
Contact
713-441-9948
[email protected]
Virginia Oncology Associates
Norfolk Virginia, 23502, United States More Info
Dr. Scott Cross
Contact
757-466-8683
[email protected]
Swedish Cancer Institute
Seattle Washington, 98104, United States More Info
Dr Patel
Contact
206-386-2301

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

75

Study ID:

NCT05336409

Recruitment Status:

Recruiting

Sponsor:


Century Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.